Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business …
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at …
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety …
Promising Update: Ocugen’s Gene Therapy for Retinitis Pigmentosa Shows Positive Results in Phase 1/2 Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week reported second quarter 2023 financial results along with a general business update.
Ocugen Provides Business Update with Second Quarter 2023 Financial Results Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company announced that it will host a conference call and live webcast to discuss the Company’s second …
Ocugen to Host Conference Call to Discuss Business Updates and Second Quarter 2023 Financial Results Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced that the Company’s Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development …
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company, announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships …
Ocugen, Inc. Announces Business Advisory Board Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company, announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, …
Ocugen to Showcase Innovative Clinical Pipeline at BIO International 2023 in Boston Read More MALVERN, PA — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company based in Chester County, Pennsylvania, recently reported first quarter 2023 financial results along with a general …
Ocugen Provides Business Update with First Quarter 2023 Financial Results Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2023 financial results and provide a …
Ocugen to Host Conference Call on Friday to Discuss Business Updates and First Quarter 2023 Financial Results Read More